Kenvue falls; Trump eyes 'important' announcement on autism findings Monday
Shares of Tylenol maker Kenvue KVUE.N fall 3.1% to $17.78 premarket
U.S. President Donald Trump said on Saturday his administration would make announcement about its autism findings on Monday, declining to offer specifics
The Wall Street Journal reported earlier this month that Health Secretary Robert F. Kennedy Jr. plans to announce that use of KVUE's popular over-the-counter pain medication Tylenol by pregnant women is potentially linked to autism, contrary to medical guidelines that say it is safe to use
Kenvue has previously said it continues to believe that taking acetaminophen - the active ingredient in Tylenol - does not cause autism
Up to last close, stock down 14.1% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

WTI and Brent Futures Both Fall Below $100 Mark, Have Oil Prices and Energy Sector Peaked?

Tradingkey








